Bioinsights has raised $2.8M in seed funding to bring AI into functional medicine, giving providers a platform to diagnose, treat, and manage chronic conditions through root-cause, evidence-based protocols.
The company's technology pairs predictive analytics and machine learning with clinical decision support, walking providers through personalized diagnostics, standardized treatment plans, and fulfillment. It also offers more than 200 standardized protocols, white-labeled supplements with direct-to-patient shipping, and productivity tools like telemedicine, AI-generated notes, and scheduling. Bioinsights frames the opportunity as an $82B market that its platform lets providers enter from day one.
